Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania. more
Time Frame | CARM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.77% | 0.49% | -0.42% |
1-Month Return | -31.98% | -3.1% | -2.2% |
3-Month Return | -49.5% | -8.59% | 2.38% |
6-Month Return | -59.03% | -4.57% | 5.1% |
1-Year Return | -82.93% | -0.94% | 23.79% |
3-Year Return | -97.13% | 2.88% | 26.66% |
5-Year Return | -97.67% | 35.84% | 81.16% |
10-Year Return | -99.82% | 98.8% | 191.72% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 11.24M | 26.54M | 9.83M | 14.92M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":42.33,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":37.05,"profit":true},{"date":"2023-12-31","value":56.2,"profit":true}] |
Cost of Revenue | 219.00K | - | 85.00K | 6.09M | 74.13M | [{"date":"2019-12-31","value":0.3,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":0.11,"profit":true},{"date":"2022-12-31","value":8.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (219.00K) | 11.24M | 26.46M | 3.74M | (59.21M) | [{"date":"2019-12-31","value":-0.83,"profit":false},{"date":"2020-12-31","value":42.47,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":14.15,"profit":true},{"date":"2023-12-31","value":-223.77,"profit":false}] |
Gross Margin | - | 100.00% | 99.68% | 38.07% | (396.85%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.68,"profit":true},{"date":"2022-12-31","value":38.07,"profit":true},{"date":"2023-12-31","value":-396.85,"profit":false}] |
Operating Expenses | 36.65M | 28.38M | 40.79M | 59.91M | 103.65M | [{"date":"2019-12-31","value":35.36,"profit":true},{"date":"2020-12-31","value":27.38,"profit":true},{"date":"2021-12-31","value":39.36,"profit":true},{"date":"2022-12-31","value":57.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (36.87M) | (28.38M) | (40.79M) | (56.16M) | (88.73M) | [{"date":"2019-12-31","value":-3687100000,"profit":false},{"date":"2020-12-31","value":-2837800000,"profit":false},{"date":"2021-12-31","value":-4079400000,"profit":false},{"date":"2022-12-31","value":-5616200000,"profit":false},{"date":"2023-12-31","value":-8873100000,"profit":false}] |
Total Non-Operating Income/Expense | - | 58.00K | 20.00K | (8.21M) | 3.79M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":1.53,"profit":true},{"date":"2021-12-31","value":0.53,"profit":true},{"date":"2022-12-31","value":-216.71,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (107.50M) | (28.35M) | (40.78M) | (61.23M) | (86.88M) | [{"date":"2019-12-31","value":-10750000000,"profit":false},{"date":"2020-12-31","value":-2834900000,"profit":false},{"date":"2021-12-31","value":-4078400000,"profit":false},{"date":"2022-12-31","value":-6122600000,"profit":false},{"date":"2023-12-31","value":-8687900000,"profit":false}] |
Income Taxes | - | (29.00K) | (10.00K) | (3.88M) | 8.10M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.36,"profit":false},{"date":"2021-12-31","value":-0.12,"profit":false},{"date":"2022-12-31","value":-47.86,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | (28.32M) | (40.77M) | (57.35M) | (94.98M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2832000000,"profit":false},{"date":"2021-12-31","value":-4077400000,"profit":false},{"date":"2022-12-31","value":-5735100000,"profit":false},{"date":"2023-12-31","value":-9497610500,"profit":false}] |
Income From Continuous Operations | - | (28.35M) | (40.78M) | (61.23M) | (86.88M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2834900000,"profit":false},{"date":"2021-12-31","value":-4078400000,"profit":false},{"date":"2022-12-31","value":-6122600000,"profit":false},{"date":"2023-12-31","value":-8687900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (107.50M) | (28.32M) | (40.77M) | (61.23M) | (86.88M) | [{"date":"2019-12-31","value":-10750000000,"profit":false},{"date":"2020-12-31","value":-2832000000,"profit":false},{"date":"2021-12-31","value":-4077400000,"profit":false},{"date":"2022-12-31","value":-6122600000,"profit":false},{"date":"2023-12-31","value":-8687900000,"profit":false}] |
EPS (Diluted) | (24.00) | (4.60) | (2.00) | (2.08) | (3.47) | [{"date":"2019-12-31","value":-2400,"profit":false},{"date":"2020-12-31","value":-460,"profit":false},{"date":"2021-12-31","value":-200,"profit":false},{"date":"2022-12-31","value":-208.09,"profit":false},{"date":"2023-12-31","value":-347,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CARM | |
---|---|
Cash Ratio | 2.55 |
Current Ratio | 3.23 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CARM | |
---|---|
ROA (LTM) | -56.08% |
ROE (LTM) | -362.79% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CARM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.26 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.26 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CARM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.97 |
P/B | 114.10 |
Price/FCF | NM |
EV/R | 0.43 |
EV/Ebitda | NM |
Carisma Therapeutics Inc. (CARM) share price today is $0.4712
Yes, Indians can buy shares of Carisma Therapeutics Inc. (CARM) on Vested. To buy Carisma Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CARM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Carisma Therapeutics Inc. (CARM) via the Vested app. You can start investing in Carisma Therapeutics Inc. (CARM) with a minimum investment of $1.
You can invest in shares of Carisma Therapeutics Inc. (CARM) via Vested in three simple steps:
The 52-week high price of Carisma Therapeutics Inc. (CARM) is $2.77. The 52-week low price of Carisma Therapeutics Inc. (CARM) is $0.38.
The price-to-earnings (P/E) ratio of Carisma Therapeutics Inc. (CARM) is
The price-to-book (P/B) ratio of Carisma Therapeutics Inc. (CARM) is 114.10
The dividend yield of Carisma Therapeutics Inc. (CARM) is 0.00%
The market capitalization of Carisma Therapeutics Inc. (CARM) is $19.67M
The stock symbol (or ticker) of Carisma Therapeutics Inc. is CARM